# Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares > research institute **Wikidata**: [Q112085441](https://www.wikidata.org/wiki/Q112085441) **Source**: https://4ort.xyz/entity/centro-de-investigacion-biomedica-en-red-enfermedades-cardiovasculares ## Summary The Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV) is a Spanish research institute dedicated to advancing biomedical research in cardiovascular diseases. Affiliated with the Carlos III Health Institute, it operates as a specialized entity under the broader framework of Spain’s biomedical research network (CIBER). Its primary mission is to investigate cardiovascular conditions through collaborative, multidisciplinary efforts. ## Key Facts - **Aliases**: CIBERCV, CIBER de Enfermedades Cardiovasculares - **Country**: Spain - **Affiliation**: Part of the Carlos III Health Institute (Instituto de Salud Carlos III) - **Classification**: Instance of a research institute - **Identifiers**: - **Ringgold ID**: 553232 - **Open Funder Registry ID**: 501100012513 - **Focus**: Specialized in cardiovascular disease research ## FAQs ### Q: What is the main focus of CIBERCV? A: CIBERCV specializes in biomedical research related to cardiovascular diseases, addressing prevention, diagnosis, and treatment through collaborative scientific efforts. ### Q: How is CIBERCV affiliated with other organizations? A: It is directly affiliated with the Carlos III Health Institute, a major public health research organization in Spain, and operates as part of the country’s networked biomedical research centers (CIBER). ### Q: What distinguishes CIBERCV from general research institutes? A: Unlike broader research institutes, CIBERCV is narrowly focused on cardiovascular health, leveraging specialized expertise and infrastructure to tackle diseases such as heart failure, hypertension, and atherosclerosis. ### Q: Is CIBERCV involved in funding research? A: While it conducts research, its funding role is tied to its affiliation with the Carlos III Health Institute, which oversees biomedical research funding and coordination in Spain. ## Why It Matters CIBERCV plays a critical role in addressing cardiovascular diseases, a leading cause of global mortality. By consolidating expertise across Spain’s biomedical research landscape, it accelerates the translation of scientific discoveries into clinical practice, improving patient outcomes and public health policies. Its integration with the Carlos III Health Institute ensures alignment with national health priorities, fostering innovation in diagnostics, therapies, and preventive strategies. As cardiovascular conditions remain a major healthcare challenge, CIBERCV’s work directly contributes to reducing disease burden and enhancing quality of life, both nationally and internationally. ## Notable For - **Specialized Focus**: Exclusively dedicated to cardiovascular disease research, unlike general medical research institutes. - **National Affiliation**: Part of Spain’s Carlos III Health Institute, a key entity in the country’s biomedical research ecosystem. - **Collaborative Model**: Operates as a networked center (CIBER), promoting interdisciplinary collaboration among researchers and clinicians. - **Recognized Identifiers**: Assigned unique IDs (Ringgold, Open Funder Registry) for precise attribution in scientific literature and funding frameworks. ## Body ### Organization Profile CIBERCV is structured as a research institute under the Spanish biomedical research network (CIBER), with a mandate to investigate cardiovascular diseases. It operates under the institutional umbrella of the Carlos III Health Institute, a public organization responsible for health research and epidemic preparedness in Spain. ### Affiliation & Funding As part of the Carlos III Health Institute, CIBERCV benefits from national funding streams and policy support for biomedical research. Its Open Funder Registry ID (501100012513) and Ringgold ID (553232) reflect its integration into global research funding and publication systems, ensuring transparency in grant allocations and scholarly output. ### Classification & Scope CIBERCV is formally classified as a research institute, distinct from universities or corporate R&D units. Its specialization in cardiovascular diseases differentiates it from general medical research entities, enabling focused investigation into conditions such as myocardial infarction, stroke, and arrhythmias. This targeted approach facilitates the development of tailored interventions and therapies. ### Research Focus The institute prioritizes translational research, bridging basic science and clinical applications. Key areas include: - **Pathophysiology**: Studying molecular mechanisms underlying cardiovascular diseases. - **Epidemiology**: Analyzing risk factors and disease prevalence in populations. - **Therapeutics**: Testing novel drugs, devices, and surgical techniques. - **Prevention**: Designing strategies for early detection and lifestyle modification. ### Collaborative Infrastructure As a networked center (CIBER), CIBERCV fosters partnerships among hospitals, universities, and research centers across Spain. This model promotes resource sharing, data pooling, and joint clinical trials, amplifying the impact of individual studies and accelerating breakthroughs. ### National & International Impact Through its affiliation with the Carlos III Health Institute, CIBERCV contributes to Spain’s strategic health research agenda. Its work aligns with global initiatives to combat non-communicable diseases (NCDs), as emphasized by the World Health Organization (WHO). By publishing findings in international journals and participating in cross-border studies, the institute influences global cardiovascular health practices. ### Governance & Transparency CIBERCV’s operations are guided by the governance frameworks of the Carlos III Health Institute, ensuring compliance with national research ethics standards and funding regulations. Its use of standardized identifiers (e.g., Open Funder Registry ID) enhances accountability in research financing and output tracking. ### Legacy & Ongoing Work While specific founding dates are not provided in the source material, CIBERCV’s establishment reflects Spain’s commitment to combating cardiovascular diseases through organized, state-backed research. Ongoing initiatives address emerging challenges, such as the intersection of cardiovascular health with aging populations and environmental factors. ## References 1. [Open Funder Registry](http://dx.doi.org/10.13039/501100012513)